Mogollón MEA, Jiménez CC, González CPL, Gómez GN

Language: Spanish
References: 10
Page: 473-477
PDF size: 260.77 Kb.

ABSTRACT

Introduction: the identification of serum haptoglobin levels has been mentioned as a related factor in cerebral vascular disease of aneurysmal origin, and may contribute to increased complications. It is a protein synthesized by the liver that binds to free hemoglobin after lysis of red blood cells and, in doing so, prevents hemoglobin-induced toxicity and facilitates clearance. Clinical studies in patients with subarachnoid hemorrhage indicate that patients with altered haptoglobin levels may be a high-risk group for bleeding-related complications and poor mortality outcomes. Objective: to determine the association of serum haptoglobin levels are predictors of mortality in aneurysmal subarachnoid hemorrhage in the Intensive Care Unit of the Bajío National Medical Center. Material and methods: observational, descriptive, longitudinal, analytical study. Conducted from March 1 to August 21, 2024 in patients admitted to the Intensive Care Unit with aneurysmal subarachnoid hemorrhage (aSAH). Serum haptoglobin values (HAPT 2) and survival of the included patients were recorded by means of non-probabilistic convenience sampling. Haptoglobin was related as a predictor of mortality. Results: twenty-seven patients who met the selection criteria were included, 17 women (63%), with a mean age of 51.48 ± 15.05, a history of systemic arterial hypertension was recorded in 13 (48.1%) and type 2 diabetes mellitus in five (18.5%) patients. Neuromonitoring with Doppler ultrasound reported ICP of 21.03 ± 4.01, ICH (intracranial hypertension) in six (22.2%); serum haptoglobin (Hapt 2) was 167.68 ± 110.4 mg/dL. Vasospasm was detected in seven (25.9%) of the patients. Not survived eight (29.6%) patients, and the mean population survival days was 109.04 ± 140.24. ROC analysis with an AUC of 0.836 (p = 0.007) 95%CI (0.680-0.991). Conclusion: in patients with aSAH we suggest using serum haptoglobin levels as a predictor of mortality.

REFERENCES

1. Neifert SN, Chapman EK, Martini ML, Shuman WH, Schupper AJ, Oermann EK, et al. Aneurysmal subarachnoid hemorrhage: the last decade. Transl Stroke Res. 2021;12(3):428-446.

2. Hoh BL, Ko NU, Amin-Hanjani S, Chou SH-Y, Cruz-Flores S, Dangayach NS, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314-e370.

3. Hugelshofer M, Sikorski CM, Seule M, Deuel J, Muroi CI, Seboek M, et al. Cell-free oxyhemoglobin in cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: biomarker and potential therapeutic target. World Neurosurg. 2018;120:e660-e666.

4. Andersen CB, Torvund-Jensen M, Nielsen MJ, de Oliveira CL, Hersleth HP, Andersen NH, et al. Structure of the haptoglobin-haemoglobin complex. Nature. 2012;489(7416):456-459.

5. Kazmi N, Koda Y, Ndiaye NC, Visvikis-Siest S, Morton MJ, Gaunt TR, et al. Genetic determinants of circulating haptoglobin concentration. Clin Chim Acta. 2019;494:138-142.

6. Murthy SB, Levy AP, Duckworth J, Schneider EB, Shalom H, Hanley DF, et al. Presence of haptoglobin-2 allele is associated with worse functional outcomes after spontaneous intracerebral hemorrhage. World Neurosurg. 2015;83(4):583-587.

7. Wu F, Liu Z, Li G, Zhou L, Huang K, Wu Z, et al. Inflammation and oxidative stress: potential targets for improving prognosis after subarachnoid hemorrhage. Front Cell Neurosci. 2021;15:739506.

8. Osgood ML. Aneurysmal subarachnoid hemorrhage: review of the pathophysiology and management strategies. Curr Neurol Neurosci Rep. 2021;21(9):50.

9. Muehlschlegel S. Subarachnoid hemorrhage. Continuum (Minneap Minn). 2018;24(6):1623-1657.

10. Okazaki T, Kuroda Y. Aneurysmal subarachnoid hemorrhage: intensive care for improving neurological outcome. J Intensive Care. 2018;6:28.